Survivorship and Radiographic Analysis of Highly Porous Acetabular Cups Designed for Improved Osseointegration Potential.

INTRODUCTION: A variety of highly porous materials have been used to obtain biological acetabular fixation after total hip arthroplasty (THA). Due to their improved surface-coated properties, new highly porous titanium metal implants have shown potential to promote prosthesis osseointegration. Therefore, the purpose of this multicenter study was to evaluate: 1) overall acetabular cup survivorship; 2) postoperative complications; and 3) radiographic signs of loosening and radiolucencies in patients who received a new highly porous titanium metal cup. MATERIALS AND METHODS: A total of 81 patients who underwent primary THA and received a new porous acetabular cup between May 16, 2013 and January 27, 2016 at three academic centers were included for analysis. There were 40 women (49%) and 41 men (51%) who had a mean age of 65 years (range, 38 to 95 years) and a mean body mass index (BMI) of 28 kg/m2 (range, 16 to 43 kg/m2). The minimum follow up time was two years and seven months (range, 2 to 4 years). The cup was engineered with fully interconnected porosity designed for potential long-term biologic fixation. Medical records were reviewed to assess for any revision surgeries and postoperative complications, and the most recent radiographs were reviewed for signs of loosening or radiolucencies. RESULTS: Overall, acetabular component survivorship, free of fixation failure or aseptic loosening, was 100%. Two patients underwent revision due to dislocations; however, revisions were performed because no constrained or dual mobility liners were available for the shell at the time. Both patients had successful outcomes and were doing well at final follow up with no further episodes of dislocation. There was one open reduction internal fixation for a periprosthetic femoral fracture, and three polyethylene revisions were performed for instability. In all of these cases, the acetabular cup was retained. On radiographic evaluation of antero-posterior pelvis radiographs, there was one patient who had radiolucencies ofsurgery, and another patient demonstrated radiolucencies ofup, both patients had non-progressive and stable findings. CONCLUSION: The results of this study demonstrated excellent survivorship, and there were no radiographic failures of this acetabular cup in primary total hip arthroplasty patients. Although two patients were found to have minimal

Surgical and Medical Costs for Fibromyalgia Patients Undergoing Total Knee Arthroplasty.

The potential added costs of managing fibromyalgia patients after total knee arthroplasty (TKA) have not been assessed. Therefore, the purpose of this study was to perform a cost analysis of fibromyalgia versus nonfibromyalgia patients who underwent TKA. Specifically, we evaluated the following episodes of care: (1) readmission rates, (2) total costs, (3) total reimbursements, and (4) net losses for surgical and medical complications. Patients who underwent TKAs between 2005 and 2014 from the Medicare Standard Analytical Files of the PearlDiver supercomputer were propensity score matched by patients with and without fibromyalgia in a 1:1 ratio based on age, sex, and the Charlson Comorbidity Index, yielding a total of 305,510 patients distributed equally between the cohorts for analysis. Odds ratios (ORs), 95% confidence intervals (CIs), and p-values were calculated. Mean costs, total costs, and total reimbursements were assessed as along with total net losses, which were defined as total costs minus total reimbursements. Fibromyalgia patients had similar 90-day readmission rates compared with nonfibromyalgia patients (OR: 1.03; 95% CI: 1.00-1.06; p = 0.06) but incurred lower readmission costs (US$2,318,384,295 vs. US$2,534,482,404; p \u3c 0.001). Although fibromyalgia patients had higher total reimbursements for medical complications ($27,758,057 vs. US$18,780,610; p \u3c 0.001), the increased management costs (US$106,049,870 vs. US$66,080,469; p \u3c 0.001) led to greater net losses (US$78,291,813 vs. US$47,299,859; p \u3c 0.001). Similarly, although fibromyalgia patients had higher total reimbursements for surgical complications (US$94,192,334 vs. US$73,969,026; p \u3c 0.001), the increased surgical costs (US$382,122,613 vs. US$306,359,910; p \u3c 0.001) led to greater net losses (US$287,930,279 vs. US$232,390,884; p \u3c 0.001). This study highlights some of the potential financial discrepancies of managing patients with fibromyalgia. Our findings suggest medical and surgical complication costs to be greater than reimbursement, resulting in overall net financial losses. These findings need to be considered in the light of health care reform and cost structuring